Braidwell LP reduced its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 79.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,707 shares of the company’s stock after selling 67,232 shares during the period. Braidwell LP’s holdings in argenex were worth $16,428,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Eastern Bank bought a new position in argenex during the 2nd quarter worth approximately $32,000. Whipplewood Advisors LLC bought a new stake in shares of argenex in the 1st quarter valued at $28,000. Sunbelt Securities Inc. acquired a new stake in shares of argenex during the third quarter worth $36,000. Axiom Investment Management LLC acquired a new stake in shares of argenex during the first quarter worth $50,000. Finally, SBI Securities Co. Ltd. raised its stake in argenex by 268.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 81 shares of the company’s stock worth $68,000 after buying an additional 59 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.
argenex Trading Up 2.6%
Shares of NASDAQ ARGX opened at $1,055.37 on Thursday. The firm has a market capitalization of $66.02 billion, a P/E ratio of 40.53, a P/E/G ratio of 1.07 and a beta of 0.47. The firm’s 50-day moving average price is $920.25 and its 200-day moving average price is $838.50. argenex SE has a 1-year low of $661.85 and a 1-year high of $1,072.75.
Analyst Ratings Changes
ARGX has been the topic of a number of research analyst reports. Piper Sandler upped their price target on shares of argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Deutsche Bank Aktiengesellschaft lowered argenex from a “buy” rating to a “hold” rating in a research report on Monday, August 24th. Citigroup upped their target price on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Citizens Jmp raised their target price on argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. Finally, Wedbush lifted their target price on argenex from $1,050.00 to $1,150.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,158.61.
Check Out Our Latest Stock Report on ARGX
argenex Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Stories
- Five stocks we like better than argenex
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
